Eric J Hsu (Eric Hsu)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Platelet Rich Plasma

Small Cell Lung Cancer

Immune Response

Top Venues

Nature communications

Journal of the National Cancer Institute

Nature biomedical engineering

Antibody therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Eric J Hsu, Timothy A Lin, Dor R Dabush, Zachary McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal Patel, Ramez Kouzy, Molly B El Alam, Sonal Noticewala, Yumeng Yang, Alexander D Sherry, Clifton D Fuller, Charles R Thomas, Chad Tang, Pavlos Msaouel, Prajnan Das, Bo Huang, Lu Tian, Ryan Sun, J Jack Lee, Tomer Meirson, Ethan Bernard Ludmir
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. Journal of the National Cancer Institute 116 (6) (2024)
Xuezhi Cao, Yong Liang, Zhenxiang Hu, Huiyu Li, Jiaming Yang, Eric J Hsu, Jiankun Zhu, Jin Zhou, Yang-Xin Fu
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nature communications 12 (1) (2021)
Diyuan Xue, Eric J Hsu, Yang-Xin Fu, Hua Peng
Next-generation cytokines for cancer immunotherapy. Antibody therapeutics 4 (2) (2021)
Longchao Liu, Jiahui Chen, Joonbeom Bae, Huiyu Li, Zhichen Sun, Casey Timmerman, Eric J Hsu, Chuanhui Han, Jian Qiao, Yang-Xin Fu
Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nature biomedical engineering 5 (11) (2021)
Eric J Hsu, Xuezhi Cao, Benjamin Moon, Joonbeom Bae, Zhichen Sun, Zhida Liu, Yang-Xin Fu
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nature communications 12 (1) (2021)
Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric J Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science immunology 4 (38) (2020)